EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieVergleichsstudieOpen Access · CC BY 4.0

Comparison of platelet‐rich plasma efficacy with and without photoactivation in melasma: A randomized double‐blind study

Filiz Topaloğlu Demir iD, Ece Altun iD

Journal of Cosmetic Dermatology · 2024-12 · 23 (12) · 3911-3917

DOI: 10.1111/jocd.16540 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Journal of Cosmetic Dermatology, online erschienen am 23.08.2024. Verfasst von Filiz Topaloğlu Demir und 1 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Medicine, Department of Dermatological and Venereal Diseases, Istanbul Medipol University, Istanbul, Turkey. Hauptthemen laut MEDLINE: Melanosis, Platelet-Rich Plasma, Quality of Life, Severity of Illness Index. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Photoactivation has been suggested to enhance the efficacy of platelet‐rich plasma (PRP) in conditions other than dermatological diseases.

Aims

To evaluate the efficacy of photoactivated PRP (P‐PRP) treatment for melasma by comparing it with non‐photoactivated, classical PRP (C‐PRP).

Methods

The study consisted of 38 female patients diagnosed with melasma between April 2022 and May 2023. The patients were randomized into the P‐PRP and C‐PRP groups. Three sessions of P‐PRP or C‐PRP were applied to the patients at 2‐week intervals. The Melasma Area and Severity Index (MASI) and Melasma Quality of Life Index (MELASQoL) scores were compared before and 2 weeks after treatment.

Results

The median age was 38 years, and the median disease duration was 60 months. Clinically, 94.7% of the cases were centrofacial and 5.3% were malar. According to Wood's lamp examination, 55.3% of the cases were epidermal, 13.2% were dermal, and 31.6% were mixed‐type. The median pre‐ and post‐treatment scores were 14.5 and 9, respectively, for MASI and 36.5 and 17, respectively, for MELASQoL. The post‐treatment MASI and MELASQoL scores of both groups significantly decreased ( p < 0.001 for both). However, the intergroup difference was not significant. When all patients were evaluated together a moderate, positive, and significant relationship was detected between PRP and the pre‐ and post‐treatment MASI and MELASQoL scores ( r = 0.494 and p = 0.002). No side effects associated with PRP were observed.

Conclusion

PRP is an effective and safe treatment method for melasma. Further studies are needed to evaluate the contribution of photoactivation to PRP treatment in melasma.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MelanosisPlatelet-Rich PlasmaQuality of LifeSeverity of Illness IndexHumansFemaleAdultDouble-Blind MethodTreatment OutcomeMiddle Aged

Stichwörter der Autor:innen

melasmaphotoactivationplatelet‐rich plasma

Autor:innen und Institutionen

  • Faculty of Medicine, Department of Dermatological and Venereal Diseases, Istanbul Medipol University, Istanbul, Turkey.

ORCID-Profile: Filiz Topaloğlu Demir, Ece Altun

Zitieren

APA

Demir, F. T., & Altun, E. (2024). Comparison of platelet‐rich plasma efficacy with and without photoactivation in melasma: A randomized double‐blind study. Journal of Cosmetic Dermatology, 23(12), 3911-3917. https://doi.org/10.1111/jocd.16540

Vancouver

Demir FT, Altun E. Comparison of platelet‐rich plasma efficacy with and without photoactivation in melasma: A randomized double‐blind study. Journal of Cosmetic Dermatology. 2024;23(12):3911-3917. doi:10.1111/jocd.16540

BibTeX
@article{Demir2024,
  author = {Demir, Filiz Topaloğlu and Altun, Ece},
  title = {Comparison of platelet‐rich plasma efficacy with and without photoactivation in melasma: A randomized double‐blind study},
  journal = {Journal of Cosmetic Dermatology},
  year = {2024},
  volume = {23},
  number = {12},
  pages = {3911--3917},
  doi = {10.1111/jocd.16540}
}
Kostenlos starten →